AbelZeta Gets FDA IND Clearance for Prizlon-cel in Large B-Cell Lymphoma - The Clinical Trial Vanguard
AbelZeta Gets FDA IND Clearance for Prizlon-cel in Large B-Cell Lymphoma The Clinical Trial Vanguard
Non-Hodgkin Lymphoma News
AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma - PR Newswire
AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma PR Newswire
Sporadic Burkitt Lymphoma Presenting as Refractory Iron-Deficiency Anemia in a Three-Year-Old Boy: A Case Report - Cureus
Sporadic Burkitt Lymphoma Presenting as Refractory Iron-Deficiency Anemia in a Three-Year-Old Boy: A Case Report Cureus
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial - Nature
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial Nature
Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma: From Clinical Trials to Clinical Practice - Journal of Nuclear Medicine
Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma: From Clinical Trials to Clinical Practice Journal of Nuclear Medicine
CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight - Yahoo Finance
CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight Yahoo Finance
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - Business Wire
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma Business Wire
Hodgkin vs. Non-Hodgkin Lymphoma: How To Tell the Difference - health.com
Hodgkin vs. Non-Hodgkin Lymphoma: How To Tell the Difference health.com
7 Signs of Non-Hodgkin Lymphoma You Shouldn’t Ignore - Hartford HealthCare
7 Signs of Non-Hodgkin Lymphoma You Shouldn’t Ignore Hartford HealthCare
Roundup Non-Hodgkin’s Lymphoma Lawsuit [2026 Update] - robertkinglawfirm.com
Roundup Non-Hodgkin’s Lymphoma Lawsuit [2026 Update] robertkinglawfirm.com
Study reveals promising new therapy for non-Hodgkin lymphoma - Medical Xpress
Study reveals promising new therapy for non-Hodgkin lymphoma Medical Xpress
Advances in lymphoma treatment: new therapies and clinical trials - Penn Medicine
Advances in lymphoma treatment: new therapies and clinical trials Penn Medicine
Inequities in Access to Rituximab and Survival in Non-Hodgkin Lymphoma: A 20-Year Cohort Study from Nigeria - European Society of Medicine
Inequities in Access to Rituximab and Survival in Non-Hodgkin Lymphoma: A 20-Year Cohort Study from Nigeria European Society of Medicine
A Rare Case of Motor Neuropathy Secondary to Non-Hodgkin Lymphoma - Cureus
A Rare Case of Motor Neuropathy Secondary to Non-Hodgkin Lymphoma Cureus
Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts - Nature
Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts Nature
National Poetry Month: "Non-Hodgkin’s Lymphoma" - The Rumpus
National Poetry Month: "Non-Hodgkin’s Lymphoma" The Rumpus
CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight - PR Newswire
CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight PR Newswire
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma - Business Wire
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma Business Wire
Beyond the Nodes: Atypical Presentations of Non-Hodgkin's Lymphoma Across Organs - Cureus
Beyond the Nodes: Atypical Presentations of Non-Hodgkin's Lymphoma Across Organs Cureus
In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas - OncLive
In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas OncLive
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes - GlobeNewswire
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes GlobeNewswire
Non-Hodgkin’s lymphoma presenting as a retroperitoneal mass in the emergency department: a case report - Frontiers
Non-Hodgkin’s lymphoma presenting as a retroperitoneal mass in the emergency department: a case report Frontiers
Enterome receives U.S. FDA Orphan Drug Designation for - GlobeNewswire
Enterome receives U.S. FDA Orphan Drug Designation for GlobeNewswire
Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma - CancerNetwork
Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma CancerNetwork
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies - Frontiers
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies Frontiers
Legend Biotech Establishes Clinical Proof-of-Concept for - GlobeNewswire
Legend Biotech Establishes Clinical Proof-of-Concept for GlobeNewswire
9 Lymphoma Warning Signs To Watch For - health.com
9 Lymphoma Warning Signs To Watch For health.com
New Diagnosis of B-cell Follicular Lymphoma Temporally Associated With Routine Vaccination: A Report of Two Cases - Cureus
New Diagnosis of B-cell Follicular Lymphoma Temporally Associated With Routine Vaccination: A Report of Two Cases Cureus
Non-Hodgkin's Lymphoma Market Size to Hit USD 26.22 Billion by 2035 - Precedence Research
Non-Hodgkin's Lymphoma Market Size to Hit USD 26.22 Billion by 2035 Precedence Research
5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma - The ASCO Post
5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma The ASCO Post
New long-term analysis suggests follicular lymphoma can be cured - Fred Hutchinson Cancer Center
New long-term analysis suggests follicular lymphoma can be cured Fred Hutchinson Cancer Center
Current treatment algorithm: diffuse large B cell lymphoma - Blood Cancer Journal - Nature
Current treatment algorithm: diffuse large B cell lymphoma - Blood Cancer Journal Nature
Andy Whitfield’s Final Battle: The Spartacus Star and Stage IV Non-Hodgkin Lymphoma - Oncodaily
Andy Whitfield’s Final Battle: The Spartacus Star and Stage IV Non-Hodgkin Lymphoma Oncodaily
Case Report: A case of jejunal T-cell non-Hodgkin lymphoma with secondary bone involvement presenting as gastrointestinal perforation - Frontiers
Case Report: A case of jejunal T-cell non-Hodgkin lymphoma with secondary bone involvement presenting as gastrointestinal perforation Frontiers
At 34, I Was Diagnosed With An Incurable Cancer. Here’s How I Beat The Odds After Being Given 3 Months To Live. - HuffPost
At 34, I Was Diagnosed With An Incurable Cancer. Here’s How I Beat The Odds After Being Given 3 Months To Live. HuffPost
Primary Pulmonary Non-Hodgkin Lymphoma: A Report of Two Cases and a Review of the Literature Emphasizing the Role of Radiotherapy - Cureus
Primary Pulmonary Non-Hodgkin Lymphoma: A Report of Two Cases and a Review of the Literature Emphasizing the Role of Radiotherapy Cureus
Markers of Lymphoma Cancer Relapse Identified - University of Missouri School of Medicine
Markers of Lymphoma Cancer Relapse Identified University of Missouri School of Medicine
New long-term analysis suggests follicular lymphoma can be cured - UW Homepage
New long-term analysis suggests follicular lymphoma can be cured UW Homepage
Girl, 11, diagnosed with cancer after doctors dismissed symptoms as tonsillitis - Warwick Nub News
Girl, 11, diagnosed with cancer after doctors dismissed symptoms as tonsillitis Warwick Nub News